Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.80 |
| ▸ | HPGD | P15428 | 5/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL982277 | 0.96 | KDM4E (0.73) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL27502941 | 0.90 | KDM4E (0.77) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL28341718 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL10793800 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL455422 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL16116234 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL4603 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL29888959 | 0.89 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL27674312 | 0.89 | KDM4E (0.74) | KDM4EHPGDALDH1A1GAASMN1; SMN2 | |
| Salicylic Acid SCHEMBL11342550 | 0.88 | KDM4E (0.73) | KDM4EHPGDALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117599110-A | Fermented composition with functions of reducing blood sugar and blood fat and delaying aging as well as preparation method and application thereof | 浙江大医德美生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-116270987-A | Traditional Chinese medicine composition with whitening, antioxidation and chloasma removing functions and preparation method thereof | 宁波御坊堂生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-109528846-A | A kind of method of Alkaloids in Plants extraction purification | 贵州理工学院 | 2019-03-29 | — | — | CN | disclosed |
| CN-108147955-A | A kind of method that curcumin is extracted from ginger | 温州瑞思生物科技有限公司 | 2018-06-12 | — | — | CN | disclosed |
| US-20160374979-A1 | Method of Treatment of Alopecia with Monoterpenoids | Cellmid Limited (AU) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374979-A1 | Method of Treatment of Alopecia with Monoterpenoids | FGF1, FGF2, FGFR1 | KDM4E 1605/4885HPGD 392/4885ALDH1A1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.